To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.
About This Bill
Committee
Latest Action · April 30, 2024
Read twice and referred to the Committee on Finance.
The MVP Act amends Medicaid and Medicare drug pricing rules to expand value-based purchasing arrangements, where manufacturers can adjust drug payments based on patient outcomes. The bill allows manufacturers to offer different pricing points for the same drug if they make the arrangement available to all states, and clarifies how these outcome-based rebates and refunds are calculated in determining drug prices for payment purposes. The legislation applies to drug manufacturers selling through Medicaid and Medicare, as well as state Medicaid agencies that can now negotiate these outcome-based deals for both outpatient and inpatient drugs. Within 180 days of enactment, federal health agencies must issue guidance and regulations implementing these changes and clarifying how the arrangements comply with anti-kickback laws. The Government Accountability Office must study the impact of these arrangements on drug access, patient outcomes, and costs by June 30, 2028.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.